These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36917626)

  • 1. Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19.
    Bergerot CD; Malhotra J; Bergerot P; Philip EJ; Castro DV; Hsu J; Mota ACA; Cardoso de Azeredo A; Neto JNM; Hutson T; Grünwald V; Bex A; Psutka SP; Rini B; Plimack ER; Master V; Albiges L; Choueiri TK; Pal S; Powles T
    Oncologist; 2023 Jun; 28(6):494-500. PubMed ID: 36917626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
    Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
    Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.
    Cella D; Motzer RJ; Rini BI; Cappelleri JC; Ramaswamy K; Hariharan S; Arondekar B; Bushmakin AG
    Value Health; 2018 Dec; 21(12):1413-1418. PubMed ID: 30502785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.
    Carmichael C; Yuh BE; Sun V; Lau C; Hsu J; Saikia J; Liu X; Wilson T; Ferrell B; Pal SK
    Clin Genitourin Cancer; 2013 Jun; 11(2):149-54. PubMed ID: 23058499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
    Luo X; Cappelleri JC; Cella D; Li JZ; Charbonneau C; Kim ST; Chen I; Motzer RJ
    Value Health; 2009 Jun; 12(4):580-6. PubMed ID: 19900256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
    Bukowski R; Cella D; Gondek K; Escudier B;
    Am J Clin Oncol; 2007 Jun; 30(3):220-7. PubMed ID: 17551296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study.
    Goebell PJ; Müller L; Hurtz HJ; Koska M; Busies S; Marschner N
    Clin Genitourin Cancer; 2016 Feb; 14(1):63-8. PubMed ID: 26520429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer.
    Bolek H; Arslan C; Basaran M; Cicin İ; Ozguroglu M; Tural D; Ürün Y
    JCO Glob Oncol; 2024 Aug; 10():e2400201. PubMed ID: 39208383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
    Trask PC; Bushmakin AG; Cappelleri JC; Tarazi J; Rosbrook B; Bycott P; Kim S; Stadler WM; Rini B
    J Cancer Surviv; 2011 Sep; 5(3):255-62. PubMed ID: 21476015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Rao D; Butt Z; Rosenbloom S; Robinson D; Von Roenn J; Kuzel TM; Cella D
    J Pain Symptom Manage; 2009 Aug; 38(2):291-8. PubMed ID: 19356897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
    Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
    Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A psychometric evaluation of the Functional assessment of cancer therapy-kidney symptom index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure.
    Rosenblad AK; Sundqvist P; Westman B; Ljungberg B
    Qual Life Res; 2021 Sep; 30(9):2663-2670. PubMed ID: 33846957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
    Cella D; Motzer RJ; Suarez C; Blum SI; Ejzykowicz F; Hamilton M; Wallace JF; Simsek B; Zhang J; Ivanescu C; Apolo AB; Choueiri TK
    Lancet Oncol; 2022 Feb; 23(2):292-303. PubMed ID: 35032437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis.
    Cella D; Michaelson MD; Bushmakin AG; Cappelleri JC; Charbonneau C; Kim ST; Li JZ; Motzer RJ
    Br J Cancer; 2010 Feb; 102(4):658-64. PubMed ID: 20104222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies.
    Denouel A; Heutte N; Escudier B; Kurtz JE; Dos Santos M; Longato N; Desrues L; Dauchy S; Lange M; Sevin E; Rieux C; Clarisse B; Castel H; Noal S; Joly F
    Clin Genitourin Cancer; 2018 Oct; 16(5):369-375.e1. PubMed ID: 30007862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer.
    Hall J; Zanotti G; Kim R; Krulewicz S; Leith A; Bailey A; Liu FX; Kearney M
    Future Oncol; 2021 Jun; 17(17):2169-2182. PubMed ID: 33631973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).
    Cella D; Yount S; Du H; Dhanda R; Gondek K; Langefeld K; George J; Bro WP; Kelly C; Bukowski R
    J Support Oncol; 2006 Apr; 4(4):191-9. PubMed ID: 16669463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.